Predictors of antibody persistence to the 7-valent pneumococcal conjugate vaccine in healthy Fijian infants at 12 months of age

被引：1
|
作者：
Lindholm, Daniel E. [1 ,2 ]
Licciardi, Paul, V [1 ,2 ]
Ratu, Felisita T. [1 ]
Mulholland, E. Kim [1 ,3 ]
Nguyen, Cattram D. [1 ,4 ]
Russell, Fiona M. [1 ,2 ]
机构：
[1] Murdoch Childrens Res Inst MCRI, Infect & Immun, Melbourne, Vic, Australia
[2] Univ Melbourne, Ctr Int Child Hlth, Dept Paediat, Melbourne, Vic, Australia
[3] London Sch Hyg & Trop Med, London, England
[4] Murdoch Childrens Res Inst, Clin Epidemiol & Biostat Unit, Melbourne, Vic, Australia
来源：
VACCINE | 2020年 / 38卷 / 33期
关键词：
Pneumococcal conjugate vaccine; Poor antibody persistence; Ethnicity; Reduced-dose schedule; Fiji; Infant; NASOPHARYNGEAL CARRIAGE; POLYSACCHARIDE VACCINE; IMMUNE-RESPONSES; CHILDREN; IMPACT;
D O I：
10.1016/j.vaccine.2020.06.025
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Little is known about the predictors of antibody persistence to pneumococcal conjugate vaccines (PCV) in the context of reduced dose schedules. In Fiji, an RCT investigated 0, 1, 2 and 3 dose schedules of 7-valent PCV administered at 6, 10 and 14 weeks of age in 364 healthy infants. This study was a post-hoc analysis of the predictors of poor antibody persistence at 12 months, prior to a booster, using univariable and multivariable analyses. The strongest predictors of poor antibody persistence as measured by serotype-specific immunoglobulin G (IgG) and opsonophagocytosis (OI) assays were being of Indigenous Fijian ethnicity (IgG: adjusted odds ratio (aOR) 3.43, p < 0.001; OI: aOR 1.96, p = 0.013) and receipt of fewer than 3 doses of PCV. These findings may help to identify which children may be at an increased risk of pneumococcal disease in the context of reduced dose primary series PCV schedules. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码：5095 / 5099
页数：5
相关论文
共 50 条
  • [31] Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States
    Senders, Shelly
    Klein, Nicola P.
    Lamberth, Erik
    Thompson, Allison
    Drozd, Jelena
    Trammel, James
    Peng, Yahong
    Giardina, Peter C.
    Jansen, Kathrin U.
    Gruber, William C.
    Scott, Daniel A.
    Watson, Wendy
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2021, 40 (10) : 944 - 951
  • [32] Pneumococcal Meningitis Vaccine Breakthroughs and Failures After Routine 7-Valent and 13-Valent Pneumococcal Conjugate Vaccination in Children in France
    Godot, Cecile
    Levy, Corinne
    Varon, Emmanuelle
    Picard, Capucine
    Madhi, Fouad
    Cohen, Robert
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2015, 34 (10) : E260 - E263
  • [33] Pneumococcal Carriage and Invasive Disease in Children Before Introduction of the 13-valent Conjugate Vaccine: Comparison With the Era Before 7-valent Conjugate Vaccine
    Sharma, Dolly
    Baughman, Wendy
    Holst, Amy
    Thomas, Stephanie
    Jackson, Delois
    Carvalho, Maria da Gloria
    Beall, Bernard
    Satola, Sarah
    Jerris, Robert
    Jain, Shabnam
    Farley, Monica M.
    Nuorti, J. Pekka
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2013, 32 (02) : E45 - E53
  • [34] Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China
    Mo, Xiuting
    Tobe, Ruoyan Gai
    Liu, Xiaoyan
    Mori, Rintaro
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2016, 35 (11) : E353 - E361
  • [35] Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway
    Steens, Anneke
    Bergsaker, Marianne A. Riise
    Aaberge, Ingeborg S.
    Ronning, Karin
    Vestrheim, Didrik F.
    VACCINE, 2013, 31 (52) : 6232 - 6238
  • [36] Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study
    Ricketson, Leah J.
    Bettinger, Julie A.
    Sadarangani, Manish
    Halperin, Scott A.
    Kellner, James D.
    VACCINE, 2022, 40 (19) : 2733 - 2740
  • [37] Periodic cycles of pneumococcal serotypes carried by children before and after 7-valent pneumococcal conjugate vaccine
    Paulo, Ana Cristina
    Sa-Leao, Raquel
    PLOS ONE, 2017, 12 (04):
  • [38] Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs
    Kapetanovic, Meliha Crnkic
    Saxne, Tore
    Truedsson, Lennart
    Geborek, Pierre
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (01)
  • [39] Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study
    Dominguez, Angela
    Ciruela, Pilar
    Jose Garcia-Garcia, Juan
    Moraga, Fernando
    de Sevilla, Mariona F.
    Selva, Laura
    Coll, Francis
    Munoz-Almagro, Carmen
    Maria Planes, Ana
    Codina, Gemma
    Jordan, Iolanda
    Esteva, Cristina
    Hernandez, Sergi
    Soldevila, Nuria
    Cardenosa, Neus
    Batalla, Joan
    Salleras, Luis
    VACCINE, 2011, 29 (48) : 9020 - 9025
  • [40] Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany
    Kieninger, Dorothee M.
    Kueper, Kathrin
    Steul, Katrin
    Juergens, Christine
    Ahlers, Norbert
    Baker, Sherryl
    Jansen, Kathrin U.
    Devlin, Carmel
    Gruber, William C.
    Emini, Emilio A.
    Scott, Daniel A.
    VACCINE, 2010, 28 (25) : 4192 - 4203
12345